|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
An Open-Label, Positive Drug-Controlled, Parallel, Multicenter Phase II Clinical Trial of the Efficacy, Safety, and Pharmacokinetics of Flonoltinib Maleate Tablets in Patients With Intermediate to High-Risk Myelofibrosis
This trial adopts a multicenter, open-label, positive drug parallel control clinical trial design, planning to enroll approximately 75 MF participants. Eligible participants will be stratified and assigned in a 1:1:1 ratio to the low-dose flonoltinib maleate tablet group, high-dose flonoltinib maleate tablet group, or the ruxolitinib tablet group. Stratification factor include the Dynamic International Prognostic Scoring System (DIPSS) risk classification (intermediate-2 and high risk)
A randomized, double-blind, placebo-controlled, dose-escalating, single-dose, oral phase I clinical study of the safety, tolerability, and pharmacokinetics of flunotinib maleate tablets in healthy adult subjects in China.
Start Date13 Mar 2024 |
Sponsor / Collaborator- |
A Randomized, Double-blind, Placebo-controlled, Dose-escalating, Single-dose, Oral Phase I Clinical Study of the Safety, Tolerability, and Pharmacokinetics of Flunotinib Maleate Tablets in Healthy Adult Subjects in China.
Evaluate the safety and tolerability of a single increasing dose of Flibanserin Maleate tablets administered orally to healthy adult Chinese subjects; preliminarily assess the pharmacokinetic characteristics of a single dose of oral Flibanserin Maleate tablets
100 Clinical Results associated with FLT3 x CDK6 x JAK2
100 Translational Medicine associated with FLT3 x CDK6 x JAK2
0 Patents (Medical) associated with FLT3 x CDK6 x JAK2
